A current evidence-focused guide to canine faecal microbiota transplantation covering chronic enteropathy, repeated versus single FMT, donor screening, delivery routes, risks and India access.

Chronic diarrhoea needs urgent care when

There is collapse or severe dehydration
Stool contains large amounts of blood or is black
Vomiting prevents water intake
Albumin is low or swelling develops
A puppy may have parvovirus
Several household or kennel dogs become ill

What FMT attempts to do

Chronic enteropathy can involve altered microbial communities, metabolites and bile-acid processing. FMT attempts to introduce a broader donor microbial ecosystem rather than one or two probiotic strains.

The procedure includes donor selection, stool processing, storage and delivery. Each step affects safety and the biological result.

Why the evidence appears contradictory

Study pattern	Finding	Interpretation
Repeated FMT in refractory chronic enteropathy	Clinical improvement and reduced corticosteroid use reported in selected dogs	Promising adjunct in a defined population
Oral FMT in tylosin-responsive enteropathy	Investigated as a way to modify recurrence and microbiome	Product and disease specific
Single rectal FMT in chronic enteropathy	Some studies report improvement	Microbiome changes are inconsistent
Recent controlled single retention enema	No clear additional clinical benefit demonstrated	One treatment may be insufficient or patient selection matters

Differences in donor, route, dose, repetition, concurrent diet and disease subtype make direct comparison difficult.

Important: A positive FMT study does not validate unscreened faeces, internet capsules or transfer between household pets.

Donor screening is central

Complete health and diet history
No chronic gastrointestinal disease
No recent antimicrobial exposure
Faecal parasite and pathogen testing
Assessment for resistant organisms
Stable body condition and normal stool
Exclusion of zoonotic and region-specific infections

A donor that looks healthy can still shed Giardia, Salmonella, Campylobacter, resistant bacteria or parasites.

What should happen before FMT

Confirm chronic enteropathy.
Exclude parasites and infectious disease.
Complete a structured diet trial.
Assess cobalamin and pancreatic function.
Review antimicrobial exposure.
Define outcome measures and follow-up.

Potential risks and limitations

Transmission of pathogens or resistant organisms
Sedation or procedural complications
Temporary diarrhoea, gas or vomiting
Failure to produce durable change
Cost and repeated visits
Uncertain optimal donor, dose and route
Interaction with ongoing diet and medicines

India-specific barriers

Routine canine FMT services and validated donor banks are limited. High rates of parasitism, antimicrobial access and variable laboratory capacity make unscreened donor use particularly unsafe.

Imported freeze-dried products need cold-chain, batch and donor-screening verification. A product described as a 'microbiome capsule' may not be an FMT product at all.

Where the field is heading

Current research is moving toward better patient selection, standardised donor screening, repeated administration and measurement of bile acids and dysbiosis.

The appropriate public message is neither miracle cure nor useless fad. FMT remains a specialist adjunct whose benefits depend on protocol and disease subtype.

Dogsvilla practical tip: Dogsvilla should never facilitate owner-to-owner stool transfer. Any FMT discussion belongs with a veterinary internal-medicine service and a documented donor-screening protocol.